More on MNPR

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-29.7% Growth)
- Ratings (9.4 Score)

Upcoming Events

- Earnings (2/17/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Monopar Therapeutics (NQ:MNPR)
Delayed: 57.61 +1.81 (3.24%)
Prev. Close $55.80  
Open$54.47 
52 Wk High$ 
52 Wk Low$ 
Day High$57.87 
Day Low$53.50 
P/E N/A  
EPS$ 
Volume169,583 


Mar 4, 2026 05:26 PM Form 4 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
Mar 4, 2026 05:25 PM Form 3 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
Mar 2, 2026 08:04 AM Monopar appoints Susan Rodriguez as chief commercial officer
Mar 2, 2026 08:02 AM Form 8-K Monopar Therapeutics For: Mar 02
Mar 2, 2026 08:00 AM Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Feb 17, 2026 04:39 PM Form SCHEDULE 13G/A Monopar Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Feb 6, 2026 09:55 AM Form SCHEDULE 13G/A Monopar Therapeutics Filed by: ASTRAZENECA PLC
Jan 30, 2026 02:32 PM Form SCHEDULE 13D/A Monopar Therapeutics Filed by: Tactic Pharma LLC
Jan 30, 2026 02:31 PM Form 4 Monopar Therapeutics For: Jan 28 Filed by: Robinson Chandler
Jan 21, 2026 06:56 AM Monopar Therapeutics (MNPR) Reiterated at Overweight by Cantor Fitzgerald: On Track
View All Articles

Entities mentioned with MNPR

View All Entities